Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does levodopa accelerate Parkinson's disease?

T Simuni1, M B Stern

  • 1University of Pennsylvania School of Medicine, Parkinson's Disease and Movement Disorders Center, Pennsylvania Hospital, Philadelphia 19107, USA. tsimuni@pahosp.com

Drugs & Aging
|July 17, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder.

NPJ Parkinson's disease·2019
Same author

Primary treatment of comminuted intertrochanteric fractures of the hip with a Leinbach prosthesis.

International orthopaedics·2016
Same author

Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder.

Parkinsonism & related disorders·2016
Same author

Back to the basics: regular exercise matters in parkinson's disease: results from the National Parkinson Foundation QII registry study.

Parkinsonism & related disorders·2014
Same author

Mobility, mood and site of care impact health related quality of life in Parkinson's disease.

Parkinsonism & related disorders·2013
Same author

Cognitive and physiological substrates of impaired sentence processing in Parkinson's disease.

Journal of cognitive neuroscience·2013
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Levodopa is the primary Parkinson's disease treatment, but concerns exist about its neurotoxicity. Current evidence suggests levodopa does not cause neurotoxicity in Parkinson's patients, though judicious use is advised.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Levodopa is the gold standard for Parkinson's disease (PD) treatment.
  • A significant debate surrounds levodopa's potential to cause nigrostriatal cell toxicity and worsen PD progression.

Purpose of the Study:

  • To review the evidence for and against levodopa-induced neurotoxicity.
  • To clarify the implications of the levodopa controversy on clinical practice regarding treatment timing and dosage.

Main Methods:

  • Review of in vitro and in vivo studies investigating levodopa's cellular effects.
  • Analysis of clinical data from patients with Parkinson's disease.

Main Results:

  • In vitro studies show some evidence of levodopa toxicity, potentially concentration-dependent and influenced by glial cells.

Related Experiment Videos

  • In vivo data in healthy subjects and PD patients do not convincingly demonstrate levodopa-induced neurotoxicity.
  • Long-term complications like dyskinesias and motor fluctuations are associated with levodopa use, independent of direct neurotoxicity.

    • Conclusions:

    • There is no definitive evidence of levodopa causing neurotoxicity in Parkinson's disease patients.
    • Levodopa should be used judiciously at the minimal clinically effective dose to manage long-term complications.